Clinical Trial Update: Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg [Phase 3]

View source ↗

Summary

Phase 3 trial comparing safety and efficacy of aliskiren (300 mg, 150 mg, and 75 mg) versus ramipril (5 mg) in essential hypertension, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension
• Hypertension

Drugs mentioned

• Ramipril (ramipril)
• Tekturna (aliskiren)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2011-03-25